Recent advances in the management of hepatitis C in the dialysis population

International Journal of Artificial Organs

Volumn 25, Issue 6, 2002, Pages 503-511

  Fabrizi, Fabrizio ^a   Lunghi, G ^a   Martin, P ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C;

ALPHA INTERFERON; ALPHA2B INTERFERON; ERYTHROPOIETIN; INTERFERON; IRON; PARACETAMOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; REBETRON; RIBAVIRIN;

ACUTE HEPATITIS; ANTIVIRAL ACTIVITY; ASTHENIA; CLINICAL TRIAL; DIGESTIVE SYSTEM DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEART DISEASE; HEMATOLOGIC DISEASE; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER DISEASE; LONG TERM CARE; MAINTENANCE THERAPY; MENTAL DISEASE; META ANALYSIS; NECROSIS; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; VIROLOGY; RENAL REPLACEMENT THERAPY; TIME;

HEPATITIS C; HUMANS; KIDNEY DISEASES; RENAL DIALYSIS; TIME FACTORS;

EID: 0035985388     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880202500604     Document Type: Review

References (76)

1. Results of a national epidemiological investigation on HCV infection among dialysis patients
2. Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian multicenter study
3. Hepatitis C virus infection in French hemodialysis units: A multicenter study
4. Hepatitis C virus infection in dialysis centers in The Netherlands: A national survey by serological and molecular methods
5. High prevalence of hepatitis C virus infection in one dialysis center in Bulgaria
6. Hepatitis C in dialysis patients in Egypt: Relationship to dialysis duration, blood transfusion, and liver disease
7. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study
8. HCV infection in haemodialysis and CAPD patients
9. Hepatitis virus infection in haemodialysis patients from Moldavia
10. Anti-HCV seropositivity among haemodialysis patients of Iranian origin
11. Hepatitis C virus sero-status in hemodialysis patients returning from holiday: Another risk factor for HCV transmission
12. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy
13. Risk of death among chronic dialysis patients infected with hepatitis C virus
14. Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients
15. Impact of hepatitis B and C virus on kidney transplantation outcome
16. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients
17. Hepatitis C virus infection and renal transplantation
18. Nephrologists' group for the study of HCV infection and L Viola. A double-blind controlled trial of recombinant interferon-α2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels
19. Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha
20. 2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment
21. Interferon-α2b treatment of chronic hepatitis C in haemodialysis patients
22. Interferon-α in chronic hepatitis C infection in dialysis patients
23. Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients
24. Effectiveness and tolerance of interferon-α2b in the treatment of chronic hepatitis C in haemodialysis patients
25. Interferon treatment for hepatitis C virus infection in patients on haemodialysis
26. Interferon treatment for chronic hepatitis C virus infection in uremic patients
27. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response
28. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-therapy
29. Interferon treatment of chronic active hepatitis C in patients with end-stage chronic renal failure
30. Treatment of HCV-related liver disease in the dialysis population: A novel challenge for clinical nephrologists
31. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study
32. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study
33. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C
34. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C
35. Genes of major histocompatibility complex class II influence chronic hepatitis C treatment with interferon in hemodialysis patients
36. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - A pilot study
37. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment
38. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant recipient candidates on hemodialysis: Results after transplantation
39. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C
40. Effect of interpheron-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C
41. Pharmacokinetics of alfa IFN-2b in chronic hepatitis C virus undergoing chronic hemodialysis or with normal renal function: Clinical implications
42. Interferon therapy for chronic hepatitis C in hemodialysis patients: Increased serum levels of interferon
43. Tolerance and pharmacokinetics of high doses of interpheron-alpha-2a in a hemodialysis patient
44. Treatment of chronic hepatitis C in special groups
45. Interferon-alpha in acute posttransfusion hepatitis C: A randomized, controlled trial
46. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis
47. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C
48. A report on therapy of interferon A-2b in patients with acute hepatitis
49. A randomized controlled trial of recombinant interferon alfa-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C
50. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha
51. Outcome of acute hepatitis C and role of alpha interferon therapy
52. A randomised controlled trial of interferon-α treatment of acute hepatitis C
53. Interferon therapy for acute posttransfusion non-A, non-B hepatitis: Response with respect to anti-hepatitis C virus antibody status
54. Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study
55. Interferon therapy for acute hepatitis C: Changes in serum markers associated with HCV and clinical effects
56. High-dose interferon-α 2b treatment prevents chronicity in acute hepatitis C. A pilot study
57. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration
58. Interferon as treatment for acute hepatitis C: A meta-analysis
59. Interferon therapy for acute hepatitis C viral infection - A review by meta-analysis
60. Quasispecies nature of hepatitis C virus and response to alpha inteferon: Significance as a predictor of direct response to interferon
61. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C
62. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection
63. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
64. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
65. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
66. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
67. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol
68. Biomedical and biotechnological applications of PEG and PM-modified proteins
69. Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin
70. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation
71. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
72. Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs
73. Pegylated (40KDA) interferon alfa-2a (Pegasys™) is unaffected by renal impairment
74. Peginterferon alfa-2a in patients with chronic hepatitis C
75. A randomised, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha 2b as initial treatment for chronic hepatitis C
76. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial